Recruiting

HIRRT

Sponsor:

Ottawa Hospital Research Institute

Code:

NCT05264285

Conditions

Acute Kidney Injury (AKI)

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Study Details

Brief summary:

Renal replacement therapy is a life-saving treatment for patients who have sudden and severe kidney failure. However, some of these patients blood pressure who receive this treatment could become unstable, thus resulting in more injuries to their kidneys and may limit the ability of kidney recovery. In order to mitigate the instability in blood pressure, the mitochondrial functions should be studied. Mitochondria are organelles within our bodies' cells that serve as the main source of energy for cell function. Kidney cells have many of these organelles and when they are damaged, it could contribute to kidney disease. At this time, it is not known whether boosting mitochondria health and function in humans could reduce the harm of instability in blood pressure.

This research study is being done to try to explore the impact of HIRRT on mitochondria health and kidney recovery by assessing critically ill patients with AKI who are undergoing SLED treatment in ICU at The Ottawa Hospital.

Conditions

Acute Kidney Injury (AKI)

Study ID

NCT05264285

Start date

Dec 6, 2021

Status verified date

Sep, 2022

Completion date

Sep 30, 2024

Anticipated

Primary completion date

Dec 1, 2023

Anticipated

Eligibility Criteria

Eligibility Criteria

Sex: All

Age: 18+

Healthy Volunteers: Not accepted

Inclusion Criteria:

  • >/=18 years;
  • Diagnosis of stage 3 AKI per Kidney Disease Improving Global Outcomes (KDIGO) AKI guidelines;
  • Starting SLED as first RRT received during current hospitalization.

Exclusion Criteria:

  • Prior kidney transplant;
  • Prior nephrectomy;
  • Any RRT in the previous year;
  • Baseline estimated glomerular filtration rate (eGFR) <15ml/min/1.73m2.

Study Design

Enrollment

60 participants

Anticipated

Interventions and Outcome Measures

Primary outcome measure

  • Change in mean arterial pressure (MAP) [ Time Frame: 24 months ]

Central Contacts and Locations

Central contacts

Jennifer Kong, MPH

613-738-8400jkong@toh.ca

Locations

The Ottawa Hospital

Recruiting

Ottawa, Ont, Canada, K2G 2H1

Contacts

Irene Watpool, RN BScN

613-737-8724iwatpool@toh.ca

More Information

Sponsor

Ottawa Hospital Research Institute

Last update posted

Sep 29, 2022

Last verified

Sep, 2022

Keywords

  • Renal replacement therapy (RRT)
  • Slow low-efficiency dialysis (SLED)
  • Metabolites
  • Nicotinamide adenine dinucleotide (NAD+)
  • Hemodynamic instability related to RRT (HIRRT)
  • Intensive care unit (ICU)

Trial information was received from ClinicalTrials.gov and was last updated on 2026-09-09. This information was provided to ClinicalTrials.gov by Ottawa Hospital Research Institute on 2022-09-29.